Marshall Wace
CBIO

Marshall Wace’s Crescent Biopharma CBIO Stock Holding History

Marshall Wace’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.69M Buy
200,780
+178,954
+820% +$2.05M ﹤0.01% 1454
2025
Q4 		$259K Sell
21,826
-21,868
-50% -$279K ﹤0.01% 2505
2025
Q3 		$520K Buy
+43,694
New +$580K ﹤0.01% 2217
2024
Q2 		– Sell
-2,175
Closed -$653K – 2717
2024
Q1 		$653K Buy
2,175
+2,046
+1,586% +$611K ﹤0.01% 1830
2023
Q4 		$30.4K Buy
+129
New +$20.1K ﹤0.01% 2096
2023
Q3 		– Sell
-1,424
Closed -$248K – 2410
2023
Q2 		$248K Sell
1,424
-739
-34% -$124K ﹤0.01% 2191
2023
Q1 		$273K Buy
2,163
+74
+4% +$16.7K ﹤0.01% 2327
2022
Q4 		$633K Buy
+2,089
New +$308K ﹤0.01% 2282
2019
Q1 		– Sell
-1,583
Closed -$1.5M – 1844
2018
Q4 		$1.5M Buy
+1,583
New +$1.9M 0.02% 800

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $758M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM